HARP News and Press, Harpoon Therapeutics Inc. From 12/11/21

Encouraging clinical activity in higher dose cohorts with 63% ORR and 88% DCR reported in 2150 µg/week cohort with 8 disease evaluable patients with relapsed/refractory multiple myeloma Tolerable safety profile with cytokine release syndrome (all Grade 1 or 2) observed in 9...

SOUTH SAN FRANCISCO, Calif., Dec. 07, 2021 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing novel T cell engagers, today announced that it will host a conference call and webcast to review the clinical status and provide an upd...

SOUTH SAN FRANCISCO, Calif., Nov. 12, 2021 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing novel T cell engagers, today presented a poster with preclinical data on its TriTAC-XR T cell engager platform at the 36th Annual Meeti...

SOUTH SAN FRANCISCO, Calif., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (Nasdaq: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today reported financial results for the third quarter ended September 30, 2021 and provided a corpor...

SOUTH SAN FRANCISCO, Calif., Nov. 09, 2021 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today announced that management will participate in two upcoming virtual investor conferences: ...

SOUTH SAN FRANCISCO, Calif., Nov. 04, 2021 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today announced that two abstracts have been accepted for poster presentation at the 63rd American So...

Julie Eastland Appointed President and Chief Executive Officer Jerry McMahon, Ph.D., Resigns from Harpoon as President and Chief Executive Officer Scott Myers, Current Member of Harpoon’s Board of Directors Named Chair, Replacing Ron Hunt Who Remains on the Board ...

SOUTH SAN FRANCISCO, Calif., Oct. 05, 2021 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today announced that an abstract with preclinical data of its TriTAC-XR T cell engager platform has b...

Gainers: Sonoma Pharmaceuticals (NASDAQ:SNOA) +33%, Evelo Biosciences (NASDAQ:EVLO) +12%, ZIVO Bioscience (NASDAQ:ZIVO) +12%, Viridian Therapeutics (NASDAQ:VRDN) +7%, Harpoon Therapeutics (NASDAQ:HARP) +7%. Losers: Altimmune (NASDAQ:ALT) -20%, ...

Sonoma Pharmaceuticals (NASDAQ:SNOA) +70% on product launch in U.S. and Europe Planet Green (NYSE:PLAG) +30%. ZIVO Bioscience (NASDAQ:ZIVO) +20%. Frequency Electronics (NASDAQ:FEIM) +17% wins contract from the Office of Naval Research for atomic clock development AGM Group...